IDO1 and melanoma: The ECHO-301/KEYNOTE-252 trial found that treatment with the IDO1 inhibitor Epacadostat did not improve overall survival or progression free survival in melanoma (58), which brings into question the utility of IDO inhibitors in a clinical setting.